5 Firms Steer PE Sale Of €1.25B Genetic Testing Co

By Benjamin Horney (July 8, 2021, 5:26 PM EDT) -- EQT will sell reproductive genetic testing services provider Igenomix to Swedish life sciences company Vitrolife at an enterprise value of €1.25 billion ($1.48 billion), the companies said Thursday, in an agreement stitched together with help from five law firms.

The deal sees EQT AB's EQT VIII fund selling Spain-based Igenomix SL to Vitrolife AB for a mixture of cash and shares, according to a statement. As part of the agreement, certain "key" Igenomix shareholders will retain a total 7% stake in Vitrolife, per the press release.

Allen & Overy LLP and White & Case LLP are serving as legal counsel to...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!